YS BIOPHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9779 USD | +2.93% |
|
+0.81% | +91.37% |
| Apr. 19 | YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 | CI |
| Apr. 18 | YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment | MT |
Valuation
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 1,022 | 1,330 | - | - |
| Enterprise Value (EV) 1 | 1,022 | 1,330 | 1,330 | 1,330 |
| P/E ratio | -7.04 x | -2.21 x | -6.48 x | 6.99 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 2.23 x | 1.61 x | 0.96 x |
| EV / Revenue | - | 2.23 x | 1.61 x | 0.96 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 93,058 | 188,328 | - | - |
| Reference price 2 | 10.99 | 7.062 | 7.062 | 7.062 |
| Announcement Date | 7/26/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 596.2 | 826.7 | 1,387 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -351.7 | -139.9 | 142 |
| Operating Margin | - | -59% | -16.93% | 10.24% |
| Earnings before Tax (EBT) 1 | - | -299 | -123.9 | 116 |
| Net income 1 | -283.5 | -297 | -121.5 | 118.4 |
| Net margin | - | -49.81% | -14.7% | 8.54% |
| EPS 2 | -1.560 | -3.190 | -1.090 | 1.010 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 7/26/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 176.3 | 96.82 | 165 | 158.1 | 175.8 | 185.3 | 199.8 | 230.1 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -113.2 | -81.67 | -49.44 | - | - | - | - |
| Operating Margin | - | -116.92% | -49.5% | -31.28% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -105.2 | -85.21 | -55.94 | - | - | - | - |
| Net income 1 | - | -105 | -77.77 | -55.34 | - | - | - | - |
| Net margin | - | -108.43% | -47.14% | -35.01% | - | - | - | - |
| EPS 2 | - | -1.130 | -0.8300 | -0.5900 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/16/23 | 1/22/24 | 4/19/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 7/26/23 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.062
CNY
Average target price
29.98
CNY
Spread / Average Target
+324.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +91.37% | 184M | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B |
- Stock Market
- Equities
- YS Stock
- Financials YS Biopharma Co., Ltd.